January 2, 2015

Value based pricing (VBP) and value based assessments (VBA) models are becoming more prominent in the UK pharma market. Accordingly, manufacturers must have clear strategic direction, goals, and objectives when conveying their value propositions to Clinical Commissioning Groups. In particular, manufacturers need to shift from being product centric to patient centric.

Senior Consultant Jill E. Sackman, D.V.M., Ph.D., and Research Analyst Mike Kuchenreuther, Ph.D., provide insight into recent developments in the UK pharmaceutical market in Value-Based Healthcare in the United Kingdom. Focusing on pricing and reimbursement challenges, they outline strategies manufacturers should consider for sustainable success.